REG-The Vanguard Group, Inc. Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

Horizon TherapeuticsAnnouncement

06/10/2023 13:45

============

  The Vanguard Group, Inc. (IRSH)
  Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

  06-Oct-2023 / 13:34 GMT/BST

  ══════════════════════════════════════════════════════════════════════════════

                                                                            Ap27

   

                                                                        FORM 8.3

   

                               IRISH TAKEOVER PANEL

                                         

    OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH
                        TAKEOVER PANEL ACT, 1997, TAKEOVER

   RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1%
                                     OR MORE

                                         

  1. KEY INFORMATION

   

   a.         Full name of discloser                    The Vanguard Group, Inc.
   b.         Owner or controller of interests and
      short positions disclosed, if different from 1(a)
                                                         
  The naming of nominee or vehicle companies is
  insufficient. For a trust, the trustee(s), settlor
  and beneficiaries must be named.
   c.         Name of offeror/offeree in relation to
      whose relevant securities this form relates       Horizon Therapeutics plc

  Use a separate form for each offeror/offeree
   d.         If an exempt fund manager connected with
      an offeror/offeree, state this and specify         
      identity of offeror/offeree (Note 1)
   e.         Date position held/dealing undertaken
                                                        05 October 2023
  For an opening position disclosure, state the latest
  practicable date prior to the disclosure
   f.           In addition to the company in 1(c)
      above, is the discloser also making disclosures
      in respect of any other party to the offer?       N/A

  If it is a cash offer or possible cash offer, state
  “N/A”

   

  2. INTERESTS AND SHORT POSITIONS

   

  If there are interests and short positions to disclose in more than one  class
  of relevant securities of the offeror or  offeree named in 1(c), copy table  2
  for each additional class of relevant security.

   

  Ap28

   

  Interests and short  positions in the  relevant securities of  the offeror  or
  offeree to which the disclosure relates following the dealing (if any)

  (Note 2)

   

  Class of relevant security                       US$0.0001 ordinary shares
  (Note 3)
                                                   Interests     Short positions
                                                  Number     %     Number    %
   1. Relevant securities owned and/or          10,477,888 4.58%              
      controlled
   2. Cash-settled derivatives                                                
   3. Stock-settled derivatives (including                                    
      options) and agreements to purchase/ sell
  Total                                         10,477,888 4.58%              

   

  All interests and all short positions should be disclosed.

   

  Details of options including  rights to subscribe for  new securities and  any
  open  stock-settled  derivative  positions  (including  traded  options),   or
  agreements to  purchase or  sell relevant  securities, should  be given  on  a
  Supplemental Form 8.

   

  3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE (Note 4)

   

  Where there have been dealings in  more than one class of relevant  securities
  of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d)  (as
  appropriate) for each additional class of relevant security dealt in.

   

  The currency of all prices and other monetary amounts should be stated.

   

  (a) Purchases and sales

   

                              Purchase/sale                      Price per unit
   Class of relevant security               Number of securities (Note 5)
                               
   US$0.0001 ordinary shares  Purchase      2,358                116.30 USD
   US$0.0001 ordinary shares  Purchase      215                  116.34 USD
   US$0.0001 ordinary shares  Sale          11,121,088           116.30 USD

   

   

   

                                                                            Ap29

   

  (b) Cash-settled derivative transactions

   

  Class of Product     Nature of dealing                     Number of  Price
  relevant description e.g. opening/ closing a long/ short   reference  per unit
  security e.g. CFD    position, increasing/ reducing a      securities (Note 5)
                       long/ short position                  (Note 6)
                                                                         

   

  (c) Stock-settled derivative transactions (including options)

   

  (i) Writing, selling, purchasing or varying

                                         

                                     Number
             Product    Writing,       of     Exercise   Type            Option
  Class of description purchasing, securities  price     e.g.    Expiry  money
  relevant  e.g. call   selling,    to which    per    American,  date   paid/
  security   option      varying     option     unit   European         received
                          etc.      relates              etc.           per unit
                                    (Note 6)
                                                                         

   

  (ii) Exercise

   

  Class of   Product   Exercising/            Exercise
  relevant description  exercised  Number of  price per
  security  e.g. call    against   securities   unit
             option                           (Note 5)
                                               

   

  (d) Other dealings (including transactions in respect of new securities) (Note
  3)

   

     Class of      Nature of dealing           Price per unit (if
     relevant      e.g. subscription,  Details    applicable)
     security     conversion, exercise              (Note 5)
   Not Applicable                               

   

  Ap30

   

  4. OTHER INFORMATION

   

  (a) Indemnity and other dealing arrangements

   

  Details of any indemnity or option arrangement, or any agreement or
  understanding, formal or informal, relating to relevant securities which may
  be an inducement to deal or refrain from dealing entered into by the person
  making the disclosure and any party to the offer or any person acting in
  concert with a party to the offer.

  Irrevocable commitments and letters of intent should not be included. If there
  are no such agreements, arrangements or understandings, state “none”
   none

   

  (b) Agreements, arrangements or understandings relating to options or
  derivatives

   

  Full details of any agreement, arrangement or understanding between the person
  disclosing and any other person relating to the voting rights of any relevant
  securities under any option referred to on this form or relating to the voting
  rights or future acquisition or disposal of any relevant securities to which
  any derivative referred to on this form is referenced. If none, this should be
  stated.
   none

   

  (c) Attachments

   

  Is a Supplemental Form 8 attached? No

   

  Date of disclosure 06 October 2023
  Contact name       Shawn Acker
  Telephone number   001-610-669-6713

   

  Public disclosures under Rule 8.3  of the Rules must  be made to a  Regulatory
  Information Service.

  ══════════════════════════════════════════════════════════════════════════════

  Dissemination of a Regulatory Announcement, transmitted by EQS Group.
  The issuer is solely responsible for the content of this announcement.

  ══════════════════════════════════════════════════════════════════════════════

   Category Code: RET - Horizon Therapeutics plc
   TIDM:          IRSH
   LEI Code:      5493002789CX3L0CJP65
   Sequence No.:  276546
   EQS News ID:   1743621


    
   End of Announcement EQS News Service

   ══════════════════════════════════════════════════════════════════════════

    1 fncls.ssp?fn=show_t_gif&application_id=1743621&application_name=news&site_id=refinitiv

References

   Visible links


============